Global Uterine Cancer Therapeutics & Diagnostics Market Size Study & Forecast, by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), by Product (Therapeutics, Diagnostics) and Regional Analys

Global Uterine Cancer Therapeutics & Diagnostics Market Size Study & Forecast, by Type of Cancer (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, Uterine Sarcoma), by Product (Therapeutics, Diagnostics) and Regional Analysis, 2023-2030

Global Uterine Cancer Therapeutics & Diagnostics Market is valued at approximately USD XX billion in 2022 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2023-2030. Uterine cancer therapeutics and diagnostics refer to the various treatments and diagnostic methods used to manage and detect uterine cancer, also known as endometrial cancer. Uterine cancer is a type of cancer that develops in the tissues of the uterus, primarily in the lining of the uterus called the endometrium. Increasing healthcare expenditure and growing awareness regarding uterine cancer treatment is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market across the globe

The increasing prevalence of uterine cancer is anticipated to drive the growth of the Uterine Cancer Therapeutics & Diagnostics Market. According to a report published by Cancer.net in 2023, approximately 417,367 individuals worldwide were diagnosed with uterine cancer in the year 2020. Also, it is estimated that over 90% of uterine cancers are found in the endometrium, which is the lining of the uterus. The growing incidence of endometrium carcinoma, primarily attributed to increasing obesity among women, is a key factor driving the Uterine Cancer Therapeutics & Diagnostics Market. Furthermore, the increasing innovation in drug development activities, as well as rising technological advancements in the healthcare sector are presenting various lucrative prospects for the market growth over the anticipated years. However, the high cost associated with the treatment of Uterine Cancer and the low success rate observed in clinical trials for cancer drugs stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Uterine Cancer Therapeutics & Diagnostics Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of branded products and the region's increasing disease prevalence. The increasing incidence of uterine cancer and the rising awareness among the general population are the key factors driving the growth of the market in this region. According to the American Cancer Society, approximately 65,620 new cases of uterine body cancer were estimated in the United States in the year 2020. Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as rapid technological advancements in diagnostics and the rapid adoption of new technologies are stipulating the regional market growth

Major market players included in this report are:
AbbVie Inc.
Ability Pharma SA
AstraZeneca PLC
BioMerieux S.A.
Danaher Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc

Recent Developments in the Market:
 In April 2022, Roche received approval from the U.S. Food and Drug Administration (FDA) for the VENTANA MMR RxDx Panel, designed for advanced or recurrent endometrial cancer patients. The panel detects microsatellite instability (MSI) and mismatch repair (MMR) deficiencies, which are molecular mechanisms that help correct errors during DNA replication. This testing enables the identification of patients who are eligible for treatment with JEMPERLI (dostarlimab-gxly), a monotherapy anti-PD1 immunotherapy developed by GlaxoSmithKline (GSK) and approved by the FDA.

Global Uterine Cancer Therapeutics & Diagnostics Market Report Scope:
 Historical Data – 2020 - 2021
 Base Year for Estimation – 2022
 Forecast period - 2023-2030
 Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
 Segments Covered - Type of Cancer, Product, Region
 Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type of Cancer:
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma

By Product:
Therapeutics
Diagnostics

By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Companies Mentioned
AbbVie Inc.
Ability Pharma SA
AstraZeneca PLC
BioMerieux S.A.
Danaher Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
GlaxoSmithKline PLC
Johnson & Johnson Services, Inc.
Merck & Co., Inc

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.